Views 176
Citations 0
From JAMA's Daily News Site
July 10, 2013

From JAMA’s Daily News Site

Author Affiliations

Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA. 2013;310(2):132. doi:10.1001/jama.2013.8331

Intravenous immunoglobulin (IVIG [Gammagard]) did not reduce cognitive decline or preserve functional abilities in patients with mild to moderate Alzheimer disease, according to a phase 3 randomized trial.

The trial enrolled 390 patients at 45 centers across the United States and Canada. Participants received IVIG or placebo every 2 weeks for 18 months. The study results did not show a statistically significant difference in the rate of cognitive decline or functional ability for those receiving IVIG compared with placebo.

First Page Preview View Large
First page PDF preview
First page PDF preview